Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02855944 · ClinicalTrials.gov registry record · Phase 3
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
A Phase 3 study, sponsored by pharmaand.
- Completed
- Registry status
- Phase 3
- Development phase
- 349
- Enrollment target
NCT02855944 is a Phase 3 study that has completed, run by pharmaand. The registered enrollment target is 349 participants.
The verdict
NCT02855944, a Phase 3 study, has completed, sponsored by pharmaand.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 349 participants
- Enrollment target
Study Summary
The purpose of this study is to determine how patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib versus chemotherapy.
Interventions
- DRUG Chemotherapy
- DRUG Rucaparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 349 participants |
| Start Date | 2017-03-01 |
| Est. Completion | 2022-09-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02855944
The ClinicalTrials.gov registry entry for NCT02855944 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 349 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is pharmaand, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Chemotherapy is the first listed.
NCT02855944 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02855944 about?
NCT02855944 is a clinical study titled "ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients". The purpose of this study is to determine how patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib versus chemotherapy.
What is the current status of trial NCT02855944?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 349 participants. The study started on 2017-03-01. Estimated completion is 2022-09-16.
What interventions are being tested in trial NCT02855944?
The interventions under investigation include: Chemotherapy (DRUG), Rucaparib (DRUG).
Who is sponsoring clinical trial NCT02855944?
This trial is sponsored by pharmaand, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.